StreetAlpha
13F holdings · Q3 2026

KVP Capital Advisors

San Francisco, CA · files as KVP Capital Advisors, LP
Know the moment KVP Capital Advisors filesYou follow KVP Capital Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1858198

KVP Capital Advisors reported 36 stocks worth $124M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (10.1%), WHWK (6.5%) and SLN (6.0%). Compared with Q2 2026, the fund opened new positions in SLN, VOGX and YARW, trimmed IRON and sold out of AXSM and SRRK.

Latest filing: what KVP Capital Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new0 added1 trimmed3 sold outBought about $10.5M · sold about $6.7M
New 4
Added 0

None

Trimmed 1
Sold out 3
  • AXSM$2.9M
  • SRRK$2.5M
  • Vyne Therapeutics $326K

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$124M−8.8% vs last quarter
Stocks held364 new · 3 sold out
Top 5 weight34.4%spread out
Turnover14%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
PRAX
Praxis Precision Medicines I
$12.5M10.1%43KNo change4 of 4
2
WHWK
Whitehawk Therapeutics Inc
$8.1M6.5%2.2MNo change4 of 4
3
SLN
Silence Therapeutics PLC
$7.5M6.0%684KNew position1 of 4
4
PTGX
Protagonist Therapeutics Inc
$7.5M6.0%53KNo change4 of 4
5
MBX
Mbx Biosciences Inc
$7.1M5.7%122KNo change4 of 4
6
ERAS
Erasca Inc
$6.7M5.4%455KNo change3 of 4
7
TRVI
Trevi Therapeutics Inc
$5.9M4.8%414KNo change4 of 4
8
TNGX
Tango Therapeutics Inc
$5.7M4.6%230KNo change3 of 4
9
EWTX
Edgewise Therapeutics Inc
$5.4M4.3%133KNo change4 of 4
10
TNDM
Tandem Diabetes Care Inc
$4.9M4.0%301KNo change2 of 4
🔒 26 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
AXSM
Axsome Therapeutics Inc
$2.9M12K
SRRK
Scholar Rock Hldg Corp
$2.5M45K
VYNE THERAPEUTICS INC C
$326K501K

Reported value

last 4 quarters
$96.8MQ4 '25
$134MQ1 '26
$136MQ2 '26
$124MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

KVP Capital Advisors 13F FAQ

What does KVP Capital Advisors own?

KVP Capital Advisors reported 36 stocks worth $124M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (10.1%), WHWK (6.5%) and SLN (6.0%). The table above lists every position in the filing (the top 10 without an account).

What did KVP Capital Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 0 added to, 1 trimmed and 3 sold out. New positions include SLN, VOGX and YARW. It sold all of AXSM and SRRK.

When will KVP Capital Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is KVP Capital Advisors's portfolio worth?

The Q3 2026 filing reports $124M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.